{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:59:36Z","timestamp":1789390776914,"version":"build-2803163510"},"reference-count":202,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,22]],"date-time":"2018-12-22T00:00:00Z","timestamp":1545436800000},"content-version":"am","delay-in-days":355,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.clml.2017.11.008","type":"journal-article","created":{"date-parts":[[2017,12,2]],"date-time":"2017-12-02T01:48:24Z","timestamp":1512179304000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["SOHO State-of-the-Art Update and Next Questions: MPN"],"prefix":"10.1016","volume":"18","author":[{"given":"Prithviraj","family":"Bose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire N.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.11.008_bib1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib3","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.11.008_bib4","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1200\/JCO.2012.46.4370","article-title":"Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene","volume":"31","author":"Rumi","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.008_bib5","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/blood-2016-10-695973","article-title":"Myeloid neoplasms with eosinophilia","volume":"129","author":"Reiter","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/ajh.23585","article-title":"Masked polycythemia vera (mPV): results of an international study","volume":"89","author":"Barbui","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.11.008_bib7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ajh.23617","article-title":"Masked polycythemia vera diagnosed according to WHO and BCSH classification","volume":"89","author":"Barbui","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.11.008_bib8","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/bjh.13080","article-title":"A\u00a0lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera","volume":"167","author":"Lussana","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.11.008_bib9","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood-2013-06-508416","article-title":"Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis","volume":"122","author":"Silver","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib10","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1056\/NEJMra1406186","article-title":"Myeloproliferative neoplasms","volume":"376","author":"Spivak","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.11.008_bib11","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ajh.23694","article-title":"Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients","volume":"89","author":"Barbui","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.11.008_bib12","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/leu.2013.380","article-title":"Rethinking the diagnostic criteria of polycythemia vera","volume":"28","author":"Barbui","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.008_bib13","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1182\/blood-2014-07-551929","article-title":"How I treat polycythemia vera","volume":"124","author":"Vannucchi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib14","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1365-2141.2009.08019.x","article-title":"A\u00a0unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process","volume":"148","author":"Barosi","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.11.008_bib15","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","article-title":"Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference","volume":"113","author":"Barosi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib16","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.11.008_bib17","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3324\/haematol.2016.143644","article-title":"Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial","volume":"101","author":"Verstovsek","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.11.008_bib18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2017.11.008_bib19","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1182\/blood-2012-05-432989","article-title":"Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-alpha in a murine model of polycythemia vera","volume":"121","author":"Mullally","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib20","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib21","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.6004\/jnccn.2017.0157","article-title":"NCCN guidelines insights: myeloproliferative neoplasms, version 2.2018","volume":"15","author":"Mesa","year":"2017","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"suppl 5","key":"10.1016\/j.clml.2017.11.008_bib22","doi-asserted-by":"crossref","first-page":"v85","DOI":"10.1093\/annonc\/mdv203","article-title":"Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Vannucchi","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2017.11.008_bib23","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S2352-3026(17)30030-3","article-title":"Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial","volume":"4","author":"Masarova","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2017.11.008_bib24","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","article-title":"Ropeginterferon alfa-2b, a novel IFNalpha-2b, induces high response rates with low toxicity in patients with polycythemia vera","volume":"126","author":"Gisslinger","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib25","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1182\/blood.V128.22.475.475","article-title":"Final results from PROUD-PV a randomized controlled phase 3 trial comparing ropeginterferon alfa-2b to hydroxyurea in polycythemia vera patients","volume":"128","author":"Gisslinger","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib26","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood.V128.22.479.479","article-title":"Interim analysis of the myeloproliferative disorders research consortium (MPD-RC) 112 global phase III trial of front line pegylated interferon alpha-2a vs. hydroxyurea in high risk polycythemia vera and essential thrombocythemia","volume":"128","author":"Mascarenhas","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib27","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1182\/blood-2005-12-4824","article-title":"Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model","volume":"107","author":"Wernig","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib28","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood-2009-04-215848","article-title":"Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease","volume":"115","author":"Akada","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib29","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2009-12-257063","article-title":"Myeloproliferative neoplasm induced by\u00a0constitutive expression of JAK2V617F in knock-in mice","volume":"116","author":"Marty","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib30","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","article-title":"Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells","volume":"17","author":"Mullally","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2017.11.008_bib31","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood-2013-06-510222","article-title":"JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease","volume":"123","author":"Li","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib32","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1182\/blood-2012-05-431791","article-title":"JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone","volume":"120","author":"Godfrey","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib33","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.11.008_bib34","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3324\/haematol.2012.079129","article-title":"Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia","volume":"98","author":"Godfrey","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.11.008_bib35","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa1403141","article-title":"Two clinical phenotypes in polycythemia vera","volume":"371","author":"Spivak","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.11.008_bib36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Advances"},{"key":"10.1016\/j.clml.2017.11.008_bib37","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/blood-2015-04-638593","article-title":"White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study","volume":"126","author":"Barbui","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib38","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1365-2141.2007.06674.x","article-title":"Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation","volume":"138","author":"Gangat","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.11.008_bib39","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","article-title":"Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera","volume":"109","author":"Landolfi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib40","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A\u00a0prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.008_bib41","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.008_bib42","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00277-009-0706-x","article-title":"Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms","volume":"88","author":"Caramazza","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2017.11.008_bib43","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1182\/blood-2012-02-410712","article-title":"Combination treatment in\u00a0vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-alpha 2a specifically targets JAK2V617F-positive polycythemia vera cells","volume":"120","author":"Lu","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib44","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood-2013-11-536854","article-title":"The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon alpha 2a target JAK2V617F-positive progenitor and stem cells","volume":"124","author":"Lu","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib45","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1080\/13543784.2016.1250882","article-title":"Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms","volume":"25","author":"Bose","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clml.2017.11.008_bib46","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.11.008_bib47","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.11.008_bib48","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/blood-2015-09-671172","article-title":"Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms","volume":"127","author":"Araki","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib49","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2015-11-681932","article-title":"Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants","volume":"127","author":"Chachoua","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib50","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/2159-8290.CD-15-1434","article-title":"Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation","volume":"6","author":"Elf","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2017.11.008_bib51","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1182\/blood-2015-11-679571","article-title":"Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis","volume":"127","author":"Marty","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib52","doi-asserted-by":"crossref","first-page":"33416","DOI":"10.18632\/oncotarget.16797","article-title":"Sequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasms","volume":"8","author":"Cavalloni","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2017.11.008_bib53","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib54","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib55","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1038\/leu.2014.148","article-title":"Calreticulin mutations and long-term survival in essential thrombocythemia","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.008_bib56","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3324\/haematol.2016.146654","article-title":"Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation","volume":"101","author":"Alvarez-Larran","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.11.008_bib57","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1038\/bcj.2015.94","article-title":"Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2017.11.008_bib58","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/leu.2016.351","article-title":"Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.008_bib59","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2015.277","article-title":"Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms","volume":"30","author":"Pietra","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.008_bib60","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ajh.24338","article-title":"Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia","volume":"91","author":"Elala","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.11.008_bib61","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","article-title":"Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia","volume":"117","author":"Passamonti","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2017.11.008_bib62","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib63","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/ajh.24293","article-title":"Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients","volume":"91","author":"Haider","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.11.008_bib64","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1182\/blood-2014-08-596676","article-title":"Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia","volume":"124","author":"Finazzi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib65","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","article-title":"A\u00a0prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment","volume":"120","author":"Passamonti","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib66","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2012-04-424911","article-title":"Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort","volume":"120","author":"Campbell","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib67","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2007.15.3569","article-title":"Leukocytosis and risk stratification assessment in essential thrombocythemia","volume":"26","author":"Carobbio","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.008_bib68","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1182\/blood-2010-03-272179","article-title":"Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria","volume":"116","author":"Carobbio","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib69","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib70","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/ajh.24882","article-title":"Gender and survival in essential thrombocythemia: a two-center study of 1,494 patients","volume":"92","author":"Tefferi","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.11.008_bib71","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/ajh.24689","article-title":"The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia","volume":"92","author":"Mudireddy","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.11.008_bib72","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.11.008_bib73","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET study, a randomized controlled trial","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib74","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.leu.2404473","article-title":"A\u00a0unified definition of clinical resistance\/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group","volume":"21","author":"Barosi","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.008_bib75","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","article-title":"The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients","volume":"109","author":"Mesa","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.11.008_bib76","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s00277-017-3082-y","article-title":"The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey","volume":"96","author":"Harrison","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2017.11.008_bib77","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood-2017-02-765032","article-title":"Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results","volume":"130","author":"Verstovsek","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib78","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1182\/blood-2017-05-785790","article-title":"Ruxolitinib versus best available therapy for ET intolerant or resistant to hydroxycarbamide in a randomized trial","volume":"130","author":"Harrison","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib79","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.leu.2405043","article-title":"Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F","volume":"22","author":"Shide","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.008_bib80","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2009-12-259747","article-title":"JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia","volume":"116","author":"Li","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib81","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1182\/blood-2013-06-501452","article-title":"JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia","volume":"122","author":"Hobbs","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib82","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1182\/blood-2009-04-218842","article-title":"Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis","volume":"115","author":"Koppikar","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib83","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/leu.2016.308","article-title":"Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib","volume":"31","author":"Shide","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.008_bib84","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1182\/blood-2013-07-514208","article-title":"Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs","volume":"123","author":"Duek","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib85","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1182\/blood-2016-05-643346","article-title":"How I treat essential thrombocythemia","volume":"128","author":"Rumi","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib86","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/bjh.14443","article-title":"Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?","volume":"176","author":"Falchi","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.11.008_bib87","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1038\/leu.2013.74","article-title":"Problems and pitfalls regarding WHO-defined diagnosis of early\/prefibrotic primary myelofibrosis versus essential thrombocythemia","volume":"27","author":"Barbui","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.008_bib88","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.008_bib89","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2012-01-407981","article-title":"Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early\/prefibrotic primary myelofibrosis","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib90","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.1182\/blood-2010-07-293761","article-title":"Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification","volume":"117","author":"Thiele","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib91","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13000-015-0269-1","article-title":"Thrombosis in essential thrombocytemia and early\/prefibrotic primary myelofibrosis: the role of the WHO histological diagnosis","volume":"10","author":"Rupoli","year":"2015","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.clml.2017.11.008_bib92","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/leu.2011.258","article-title":"Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria","volume":"26","author":"Finazzi","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.008_bib93","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/ajh.23217","article-title":"Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early\/prefibrotic myelofibrosis: an international study of 264 patients","volume":"87","author":"Buxhofer-Ausch","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.11.008_bib94","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/bjh.14202","article-title":"Impact of white blood cell counts at diagnosis and during follow-up in patients with essential thrombocythaemia and prefibrotic primary myelofibrosis","volume":"179","author":"Buxhofer-Ausch","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.11.008_bib95","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2017-01-761999","article-title":"Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis","volume":"129","author":"Guglielmelli","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib96","doi-asserted-by":"crossref","unstructured":"Mudireddy M, Shah S, Lasho T, et\u00a0al. Prefibrotic versus overtly fibrotic primary myelofibrosis: clinical, cytogenetic, molecular and prognostic comparisons [e-pub ahead of print]. Br J Haematol https:\/\/doi.org\/10.1111\/bjh.14838.","DOI":"10.1111\/bjh.14838"},{"key":"10.1016\/j.clml.2017.11.008_bib97","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia","volume":"342","author":"Tefferi","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.11.008_bib98","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/bjh.14269","article-title":"Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera","volume":"175","author":"Delic","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.11.008_bib99","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib100","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1084\/jem.20160283","article-title":"Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis","volume":"213","author":"Verstovsek","year":"2016","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.clml.2017.11.008_bib101","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.stem.2017.03.008","article-title":"Gli1+ mesenchymal stromal cells are a key driver of bone marrow fibrosis and an important cellular therapeutic target","volume":"20","author":"Schneider","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.clml.2017.11.008_bib102","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.3109\/10428194.2014.984703","article-title":"Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis","volume":"56","author":"Sasaki","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.11.008_bib103","doi-asserted-by":"crossref","unstructured":"Ruberti S, Bianchi E, Guglielmelli P, et\u00a0al. Involvement of MAF\/SPP1 axis in the development of bone marrow fibrosis in PMF patients [e-pub ahead of print]. Leukemia https:\/\/doi.org\/10.1038\/leu.2017.220.","DOI":"10.1038\/leu.2017.220"},{"key":"10.1016\/j.clml.2017.11.008_bib104","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/cncr.29842","article-title":"The evolution and clinical relevance of prognostic classification systems in myelofibrosis","volume":"122","author":"Bose","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.11.008_bib105","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1200\/JCO.2009.22.8833","article-title":"Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis","volume":"27","author":"Tam","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.008_bib106","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1182\/blood-2011-08-371096","article-title":"Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients","volume":"118","author":"Tefferi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib107","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib108","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.008_bib109","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.008_bib110","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.76","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients","volume":"28","author":"Guglielmelli","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.008_bib111","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood.V124.21.405.405","article-title":"Mutation-Enhanced International Prognostic Scoring System (MIPSS) for primary myelofibrosis: an AGIMM & IWG-MRT Project","volume":"124","author":"Vannucchi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib112","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3324\/haematol.2016.149765","article-title":"An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis","volume":"102","author":"Rozovski","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.11.008_bib113","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/blood.V124.21.406.406","article-title":"Integration of mutations and karyotype towards a Genetics-Based Prognostic Scoring System (GPSS) for primary myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib114","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/leu.2014.83","article-title":"Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.008_bib115","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1038\/bcj.2015.90","article-title":"Validation of the differential prognostic impact of type 1\/type 1-like versus type 2\/type 2-like CALR mutations in myelofibrosis","volume":"5","author":"Guglielmelli","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2017.11.008_bib116","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2014.57","article-title":"CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.008_bib117","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/ajh.24442","article-title":"Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients","volume":"91","author":"Guglielmelli","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.11.008_bib118","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/leu.2014.343","article-title":"CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis","volume":"29","author":"Finazzi","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.008_bib119","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1038\/bcj.2015.95","article-title":"Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors","volume":"5","author":"Cerquozzi","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2017.11.008_bib120","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2014-07-575373","article-title":"How I treat myelofibrosis","volume":"124","author":"Cervantes","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib121","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.3324\/haematol.2013.101733","article-title":"The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis","volume":"99","author":"Hernandez-Boluda","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.11.008_bib122","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.3324\/haematol.2016.149013","article-title":"Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera\/essential thrombocytosis myelofibrosis","volume":"101","author":"Gowin","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.11.008_bib123","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.leukres.2017.06.001","article-title":"Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis","volume":"59","author":"Masarova","year":"2017","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2017.11.008_bib124","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1038\/leu.2017.268","article-title":"Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis","volume":"31","author":"Tefferi","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.008_bib125","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood-2007-11-121434","article-title":"A\u00a0dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis","volume":"111","author":"Passamonti","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib126","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1002\/cncr.21868","article-title":"Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis","volume":"106","author":"Dingli","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.11.008_bib127","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A\u00a0clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.008_bib128","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1158\/1078-0432.CCR-12-0653","article-title":"U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis","volume":"18","author":"Deisseroth","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2017.11.008_bib129","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2017.11.008_bib130","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.008_bib131","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A\u00a0double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.11.008_bib132","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3324\/haematol.2013.092155","article-title":"Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I","volume":"98","author":"Verstovsek","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.11.008_bib133","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","volume":"122","author":"Cervantes","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib134","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00277-017-2994-x","article-title":"Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study","volume":"96","author":"Vannucchi","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2017.11.008_bib135","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2015-03-635235","article-title":"The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis","volume":"126","author":"Deininger","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib136","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1080\/10428194.2016.1195501","article-title":"Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence","volume":"57","author":"Harrison","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.11.008_bib137","doi-asserted-by":"crossref","first-page":"TPS7080","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS7080","article-title":"ReTHINK: a randomized, double-blind, placebo-controlled, multicenter, phase 3 study of ruxolitinib in early myelofibrosis patients","volume":"34","author":"Passamonti","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.008_bib138","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.6004\/jnccn.2016.0169","article-title":"Myeloproliferative neoplasms, version 2.2017, NCCN clinical practice guidelines in oncology","volume":"14","author":"Mesa","year":"2016","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2017.11.008_bib139","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/leu.2016.283","article-title":"Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations","volume":"31","author":"Marchetti","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.008_bib140","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1038\/leu.2016.45","article-title":"JAK2(V617F) allele burden 50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy","volume":"30","author":"Barosi","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.008_bib141","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/bjh.12274","article-title":"The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis","volume":"161","author":"Verstovsek","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.11.008_bib142","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.11.008_bib143","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/blood-2012-02-414631","article-title":"Long-term outcomes of 107 patients with myelofibrosis receiving JAK1\/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls","volume":"120","author":"Verstovsek","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib144","first-page":"156","article-title":"A\u00a0pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis","volume":"10","author":"Vannucchi","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.11.008_bib145","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2015-03-633404","article-title":"Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib","volume":"126","author":"Patel","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib146","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib147","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.3324\/haematol.2016.151449","article-title":"The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies","volume":"101","author":"Gupta","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.11.008_bib148","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.3109\/10428194.2016.1146950","article-title":"Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis","volume":"57","author":"Al-Ali","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.11.008_bib149","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.beha.2014.07.011","article-title":"Does anything work for anaemia in myelofibrosis?","volume":"27","author":"Birgegard","year":"2014","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.clml.2017.11.008_bib150","doi-asserted-by":"crossref","first-page":"166.e17","DOI":"10.1016\/j.exphem.2012.12.002","article-title":"Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap","volume":"41","author":"Iancu-Rubin","year":"2013","journal-title":"Exp Hematol"},{"key":"10.1016\/j.clml.2017.11.008_bib151","first-page":"255","article-title":"Sotatercept (ACE-011) Alone and in Combination with Ruxolitinib in Patients (pts) with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Anemia","volume":"130","author":"Bose","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib152","first-page":"256","article-title":"Interim Phase 2 Clinical Trial Results for LCL161, an Oral Smac Mimetic, in Patients with Intermediate or High Risk Myelofibrosis","volume":"130","author":"Pemmaraju","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib153","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","article-title":"TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms","volume":"118","author":"Fleischman","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib154","first-page":"1058","article-title":"Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis","volume":"100","author":"Daver","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.11.008_bib155","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1182\/blood.V126.23.826.826","article-title":"A\u00a0phase-Ib\/II study of ruxolitinib plus pomalidomide in myelofibrosis","volume":"126","author":"Stegelmann","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib156","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1182\/blood-2002-09-2928","article-title":"A\u00a0phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia","volume":"101","author":"Mesa","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib157","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2004.08.160","article-title":"Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial","volume":"22","author":"Marchetti","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.008_bib158","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3324\/haematol.12416","article-title":"Low-dose thalidomide in myelofibrosis","volume":"93","author":"Weinkove","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.11.008_bib159","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/13543784.2017.1323871","article-title":"Investigational Janus kinase inhibitors in development for myelofibrosis","volume":"26","author":"Bose","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clml.2017.11.008_bib160","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/nchembio.1471","article-title":"Dual kinase-bromodomain inhibitors for rationally designed polypharmacology","volume":"10","author":"Ciceri","year":"2014","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.clml.2017.11.008_bib161","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2017.11.008_bib162","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2017.11.008_bib163","doi-asserted-by":"crossref","first-page":"7000","DOI":"10.1200\/JCO.2017.35.15_suppl.7000","article-title":"Phase 3 trial of momelotinib (MMB) vs ruxolitinib (RUX) in JAK inhibitor (JAKi) naive patients with myelofibrosis (MF)","volume":"35","author":"Mesa","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.008_bib164","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1200\/JCO.2017.35.15_suppl.7001","article-title":"Phase 3 randomized trial of momelotinib (MMB) versus best available therapy (BAT) in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX)","volume":"35","author":"Harrison","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.008_bib165","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy\u00a0for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2017.11.008_bib166","doi-asserted-by":"crossref","first-page":"LBA-5","DOI":"10.1182\/blood.V128.22.LBA-5.LBA-5","article-title":"Results of the persist-2 phase 3 study of pacritinib (PAC) versus best available therapy (BAT), including ruxolitinib (RUX), in patients (pts) with myelofibrosis (MF) and platelet counts\u00a0<100,000\/\u03bcL","volume":"128","author":"Mascarenhas","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib167","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1182\/blood.V128.22.1936.1936","article-title":"Phase 1\/2 study of NS-018, an oral JAK2 inhibitor, in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (postPV MF), or post-essential thrombocythemia myelofibrosis (postET MF)","volume":"128","author":"Verstovsek","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib168","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3324\/haematol.2016.151126","article-title":"Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis","volume":"102","author":"Mascarenhas","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.11.008_bib169","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1182\/blood-2016-10-695965","article-title":"Emerging treatments for classical myeloproliferative neoplasms","volume":"129","author":"Vannucchi","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib170","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/blood-2017-04-742288","article-title":"JAK2 inhibitors for myeloproliferative neoplasms: what is next?","volume":"130","author":"Bose","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib171","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa1310523","article-title":"A\u00a0pilot study of the telomerase inhibitor imetelstat for myelofibrosis","volume":"373","author":"Tefferi","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.11.008_bib173","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.V124.21.713.713","article-title":"Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: stage 1 results","volume":"124","author":"Verstovsek","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib174","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/blood.V126.23.56.56","article-title":"PRM-151 in myelofibrosis: durable efficacy and safety at 72 weeks","volume":"126","author":"Verstovsek","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib175","doi-asserted-by":"crossref","first-page":"6230","DOI":"10.1158\/1078-0432.CCR-13-0905","article-title":"JAK1\/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease","volume":"19","author":"Evrot","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2017.11.008_bib176","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1182\/blood-2009-05-222133","article-title":"Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells","volume":"114","author":"Wang","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib177","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/blood-2014-01-547760","article-title":"Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms","volume":"123","author":"Bhagwat","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib178","doi-asserted-by":"crossref","first-page":"7347","DOI":"10.1158\/1078-0432.CCR-11-1541","article-title":"Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells","volume":"17","author":"Fiskus","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2017.11.008_bib179","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/jcmm.12162","article-title":"Co-targeting the PI3K\/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms","volume":"17","author":"Bartalucci","year":"2013","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.clml.2017.11.008_bib180","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/1535-7163.MCT-12-0862","article-title":"Dual PI3K\/AKT\/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells","volume":"12","author":"Fiskus","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2017.11.008_bib181","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1182\/blood.V128.22.1127.1127","article-title":"Ruxolitinib (RUX) in combination with 5-azacytidine (AZA) as therapy for patients (pts) with myelofibrosis (MF)","volume":"128","author":"Daver","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib182","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1182\/blood.V126.23.4060.4060","article-title":"Efficacy, safety, and confirmation of the recommended phase 2 starting dose of the combination of ruxolitinib (RUX) and panobinostat (PAN) in patients (Pts) with myelofibrosis (MF)","volume":"126","author":"Harrison","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib183","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood.V128.22.634.634","article-title":"Synergistic therapeutic efficacy of combined JAK1\/2, Pan-PIM, and CDK4\/6 inhibition in myeloproliferative neoplasms","volume":"128","author":"Rampal","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib184","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.celrep.2013.10.038","article-title":"Combined targeting of JAK2 and Bcl-2\/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors","volume":"5","author":"Waibel","year":"2013","journal-title":"Cell Rep"},{"key":"10.1016\/j.clml.2017.11.008_bib185","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood.V128.22.636.636","article-title":"Selective inhibition of nuclear cytoplasmic transport as a new treatment paradigm in myelofibrosis","volume":"128","author":"Yan","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib186","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/leu.2016.260","article-title":"BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells","volume":"31","author":"Saenz","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.008_bib187","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1038\/leu.2016.393","article-title":"Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells","volume":"31","author":"Saenz","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.008_bib188","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1182\/blood-2016-11-731604","article-title":"Does ruxolitinib prolong the survival of patients with myelofibrosis?","volume":"129","author":"Cervantes","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib189","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1182\/blood-2013-02-482232","article-title":"A\u00a0comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis","volume":"121","author":"Mascarenhas","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib190","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1158\/1078-0432.CCR-12-1907","article-title":"Intrinsic resistance to JAK2 inhibition in myelofibrosis","volume":"19","author":"Kalota","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2017.11.008_bib191","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1084\/jem.20111694","article-title":"Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition","volume":"209","author":"Weigert","year":"2012","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.clml.2017.11.008_bib192","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nature11303","article-title":"Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy","volume":"489","author":"Koppikar","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.clml.2017.11.008_bib193","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2015.06.006","article-title":"CHZ868, a type II JAK2 inhibitor, reverses type I JAK inhibitor persistence and demonstrates efficacy in myeloproliferative neoplasms","volume":"28","author":"Meyer","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2017.11.008_bib194","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.11.008_bib195","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib196","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2015.284","article-title":"Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.008_bib197","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1038\/leu.2016.190","article-title":"Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2\/ASXL1\/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.008_bib198","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/leu.2015.4","article-title":"Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event","volume":"29","author":"Jawhar","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.008_bib199","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2017-01-764423","article-title":"Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers","volume":"130","author":"Jawhar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib200","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1182\/blood.V126.23.568.568","article-title":"Blu-285, a potent and selective inhibitor for hematologic malignancies with KIT exon 17 mutations","volume":"126","author":"Evans","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib201","doi-asserted-by":"crossref","first-page":"11030","DOI":"10.1200\/JCO.2016.34.15_suppl.11030","article-title":"Efficacy of BLU-285, a novel, potent inhibitor of exon 17 mutant KIT and PDGFRA D842V, in patient-derived xenograft model of gastrointestinal stromal tumor (GIST)","volume":"34","author":"Gebreyohannes","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.008_bib202","first-page":"2","article-title":"Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (AdvSM)","volume":"130","author":"DeAngelo","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.008_bib203","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood.V128.22.1965.1965","article-title":"The multi-kinase inhibitor DCC-2618 inhibits proliferation and survival of neoplastic mast cells and other cell types involved in systemic mastocytosis","volume":"128","author":"Schneeweiss","year":"2016","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017318141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017318141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:31:04Z","timestamp":1761870664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017318141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":202,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S2152265017318141"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.11.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State-of-the-Art Update and Next Questions: MPN","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}